Pulmonary arterial dysfunction in insulin resistant obese Zucker rats

Respiratory Research

Volumn 12, Issue 1, 2011, Pages

  Moral Sanz, Javier ^a,b   Menendez, Carmen ^a,b   Moreno, Laura ^a,b   Moreno, Enrique ^a,b   Cogolludo, Angel ^a,b   Perez Vizcaino, Francisco ^a,b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ALPHA METHYLSEROTONIN; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; N [3 (AMINOMETHYL)BENZYL]ACETAMIDINE; N(G) NITROARGININE METHYL ESTER; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; POTASSIUM CHANNEL KV1.5; SEROTONIN 2A RECEPTOR; BMPR2 PROTEIN, RAT; ENZYME INHIBITOR; KCNA5 PROTEIN, RAT; MESSENGER RNA; NOS2 PROTEIN, RAT; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

5 HT2A RECEPTOR GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BMPR2 GENE; BODY WEIGHT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CURRENT DENSITY; GENE EXPRESSION; HEART VENTRICLE HYPERTROPHY; HYPOXIA; INOS GENE; INSULIN RESISTANCE; KV1 5 GENE; MALE; NONHUMAN; OBESITY; PATCH CLAMP TECHNIQUE; POTASSIUM CURRENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PULMONARY ARTERIAL DYSFUNCTION; PULMONARY ARTERY SMOOTH MUSCLE CELL; PULMONARY VASCULAR DISEASE; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; CELL MEMBRANE POTENTIAL; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HEART RIGHT VENTRICLE HYPERTROPHY; HEMODYNAMICS; IDIOPATHIC PULMONARY HYPERTENSION; METABOLISM; PATCH CLAMP; PATHOPHYSIOLOGY; PULMONARY ARTERY; PULMONARY HYPERTENSION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; ZUCKER RAT;

ANIMALS; BLOTTING, WESTERN; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HEMODYNAMICS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; INSULIN RESISTANCE; KV1.5 POTASSIUM CHANNEL; MALE; MEMBRANE POTENTIALS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NITRIC OXIDE SYNTHASE TYPE II; OBESITY; PATCH-CLAMP TECHNIQUES; PULMONARY ARTERY; RATS; RATS, ZUCKER; RECEPTOR, SEROTONIN, 5-HT2A; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 79955021792     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-12-51     Document Type: Article

References (45)

1. Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, McMurtry IF, Stenmark KR, Thistlethwaite PA, Weissmann N, et al.: Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009, 54:S20-31.
2. Cogolludo A, Moreno L, Villamor E: Mechanisms controlling vascular tone in pulmonary arterial hypertension: implications for vasodilator therapy. Pharmacology 2007, 79:65-75.
3. Chan SY, Loscalzo J: Pathogenic mechanisms of pulmonary arterial hypertension. J Mol Cell Cardiol 2008, 44:14-30.
4. Atkinson C, Stewart S, Upton PD, Machado R, Thomson JR, Trembath RC, Morrell NW: Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 2002, 105:1672-1678.
5. Morty RE, Nejman B, Kwapiszewska G, Hecker M, Zakrzewicz A, Kouri FM, Peters DM, Dumitrascu R, Seeger W, Knaus P, et al.: Dysregulated bone morphogenetic protein signaling in monocrotaline-induced pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2007, 27:1072-1078.
6. Takahashi H, Goto N, Kojima Y, Tsuda Y, Morio Y, Muramatsu M, Fukuchi Y: Downregulation of type II bone morphogenetic protein receptor in hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2006, 290:L450-458.
7. Long L, MacLean MR, Jeffery TK, Morecroft I, Yang X, Rudarakanchana N, Southwood M, James V, Trembath RC, Morrell NW: Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice. Circ Res 2006, 98:818-827.
8. Lopez-Lopez JG, Moral-Sanz J, Frazziano G, Gomez-Villalobos MJ, Flores-Hernandez J, Monjaraz E, Cogolludo A, Perez-Vizcaino F: Diabetes induces pulmonary artery endothelial dysfunction by NADPH oxidase induction. Am J Physiol Lung Cell Mol Physiol 2008, 295:L727-732.
9. Rodat L, Savineau JP, Marthan R, Guibert C: Effect of chronic hypoxia on voltage-independent calcium influx activated by 5-HT in rat intrapulmonary arteries. Pflugers Arch 2007, 454:41-51.
10. Csiszar A, Labinskyy N, Olson S, Pinto JT, Gupte S, Wu JM, Hu F, Ballabh P, Podlutsky A, Losonczy G, et al.: Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats. Hypertension 2009, 54:668-675.
11. Hironaka E, Hongo M, Sakai A, Mawatari E, Terasawa F, Okumura N, Yamazaki A, Ushiyama Y, Yazaki Y, Kinoshita O: Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Cardiovasc Res 2003, 60:692-699.
12. Cogolludo A, Perez-Vizcaino F: 5-HT receptors and K(V) channel internalization. Adv Exp Med Biol 2010, 661:391-401.
13. Remillard CV, Tigno DD, Platoshyn O, Burg ED, Brevnova EE, Conger D, Nicholson A, Rana BK, Channick RN, Rubin LJ, et al.: Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension. Am J Physiol Cell Physiol 2007, 292:C1837-1853.
14. Yuan JX, Aldinger AM, Juhaszova M, Wang J, Conte JV Jr, Gaine SP, Orens JB, Rubin LJ: Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 1998, 98:1400-1406.
15. Kirk EP, Klein S: Pathogenesis and pathophysiology of the cardiometabolic syndrome. J Clin Hypertens (Greenwich) 2009, 11:761-765.
16. Cherian B, Meka N, Katragadda S, Arora R: Therapeutic implications of diabetes in cardiovascular disease. Am J Ther 2009, 16:e51-59.
17. Fouty B: Diabetes and the pulmonary circulation. Am J Physiol Lung Cell Mol Physiol 2008, 295:L725-726.
18. Zamanian RT, Hansmann G, Snook S, Lilienfeld D, Rappaport KM, Reaven GM, Rabinovitch M, Doyle RL: Insulin resistance in pulmonary arterial hypertension. Eur Respir J 2009, 33:318-324.
19. Movahed MR, Hashemzadeh M, Jamal MM: The prevalence of pulmonary embolism and pulmonary hypertension in patients with type II diabetes mellitus. Chest 2005, 128:3568-3571.
20. Robbins IM, Newman JH, Johnson RF, Hemnes AR, Fremont RD, Piana RN, Zhao DX, Byrne DW: Association of the metabolic syndrome with pulmonary venous hypertension. Chest 2009, 136:31-36.
21. Hansmann G, Wagner RA, Schellong S, Perez VA, Urashima T, Wang L, Sheikh AY, Suen RS, Stewart DJ, Rabinovitch M: Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation 2007, 115:1275-1284.
22. Fredersdorf S, Thumann C, Ulucan C, Griese DP, Luchner A, Riegger GA, Kromer EP, Weil J: Myocardial hypertrophy and enhanced left ventricular contractility in Zucker diabetic fatty rats. Cardiovasc Pathol 2004, 13:11-19.
23. Romanko OP, Stepp DW: Reduced constrictor reactivity balances impaired vasodilation in the mesenteric circulation of the obese Zucker rat. Am J Physiol Heart Circ Physiol 2005, 289:H2097-2102.
24. Song D, Yao R, Pang CC: Altered vasodilator role of nitric oxide synthase in the pancreas, heart and brain of rats with spontaneous type 2 diabetes. Eur J Pharmacol 2008, 591:177-181.
25. Cogolludo A, Moreno L, Lodi F, Frazziano G, Cobeno L, Tamargo J, Perez-Vizcaino F: Serotonin inhibits voltage-gated K+ currents in pulmonary artery smooth muscle cells: role of 5-HT2A receptors, caveolin-1, and KV1.5 channel internalization. Circ Res 2006, 98:931-938.
26. Cogolludo A, Moreno L, Frazziano G, Moral-Sanz J, Menendez C, Castaneda J, Gonzalez C, Villamor E, Perez-Vizcaino F: Activation of neutral sphingomyelinase is involved in acute hypoxic pulmonary vasoconstriction. Cardiovasc Res 2009, 82:296-302.
27. Cogolludo A, Moreno L, Lodi F, Tamargo J, Perez-Vizcaino F: Postnatal maturational shift from PKCzeta and voltage-gated K+ channels to RhoA/Rho kinase in pulmonary vasoconstriction. Cardiovasc Res 2005, 66:84-93.
28. Takaya K, Ogawa Y, Isse N, Okazaki T, Satoh N, Masuzaki H, Mori K, Tamura N, Hosoda K, Nakao K: Molecular cloning of rat leptin receptor isoform complementary DNAs--identification of a missense mutation in Zucker fatty (fa/fa) rats. Biochem Biophys Res Commun 1996, 225:75-83.
29. Osmond JM, Mintz JD, Dalton B, Stepp DW: Obesity increases blood pressure, cerebral vascular remodeling, and severity of stroke in the Zucker rat. Hypertension 2009, 53:381-386.
30. Al-Shafei AI, Wise RG, Gresham GA, Bronns G, Carpenter TA, Hall LD, Huang CL: Non-invasive magnetic resonance imaging assessment of myocardial changes and the effects of angiotensin-converting enzyme inhibition in diabetic rats. J Physiol 2002, 538:541-553.
31. Frisbee JC: Reduced nitric oxide bioavailability contributes to skeletal muscle microvessel rarefaction in the metabolic syndrome. Am J Physiol Regul Integr Comp Physiol 2005, 289:R307-R316.
32. Villalba N, Martinez P, Briones AM, Sanchez A, Salaices M, Garcia-Sacristan A, Hernandez M, Benedito S, Prieto D: Differential structural and functional changes in penile and coronary arteries from obese Zucker rats. Am J Physiol Heart Circ Physiol 2009, 297:H696-707.
33. Serpillon S, Floyd BC, Gupte RS, George S, Kozicky M, Neito V, Recchia F, Stanley W, Wolin MS, Gupte SA: Superoxide production by NAD(P)H oxidase and mitochondria is increased in genetically obese and hyperglycemic rat heart and aorta before the development of cardiac dysfunction. The role of glucose-6-phosphate dehydrogenase-derived NADPH. Am J Physiol Heart Circ Physiol 2009, 297:H153-162.
34. Stehouwer CD, Lambert J, Donker AJ, van Hinsbergh VW: Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 1997, 34:55-68.
35. Jay D, Hitomi H, Griendling KK: Oxidative stress and diabetic cardiovascular complications. Free Radic Biol Med 2006, 40:183-192.
36. Coggins MP, Bloch KD: Nitric oxide in the pulmonary vasculature. Arterioscler Thromb Vasc Biol 2007, 27:1877-1885.
37. Toblli J, Cao G, Rivas C, Munoz M, Giani J, Dominici F, Angerosa M: Cardiovascular protective effects of nebivolol in Zucker diabetic fatty rats. J Hypertens 2010, 28:1007-1019.
38. Fulton D, Harris MB, Kemp BE, Venema RC, Marrero MB, Stepp DW: Insulin resistance does not diminish eNOS expression, phosphorylation, or binding to HSP-90. Am J Physiol Heart Circ Physiol 2004, 287:H2384-2393.
39. Gurney AM, Howarth FC: Effects of streptozotocin-induced diabetes on the pharmacology of rat conduit and resistance intrapulmonary arteries. Cardiovasc Diabetol 2009, 8:4.
40. Song D, Kuo KH, Yao R, Hutchings SR, Pang CC: Inducible nitric oxide synthase depresses cardiac contractile function in Zucker diabetic fatty rats. Eur J Pharmacol 2008, 579:253-259.
41. Gunnett CA, Heistad DD, Faraci FM: Gene-targeted mice reveal a critical role for inducible nitric oxide synthase in vascular dysfunction during diabetes. Stroke 2003, 34:2970-2974.
42. Noronha BT, Li JM, Wheatcroft SB, Shah AM, Kearney MT: Inducible nitric oxide synthase has divergent effects on vascular and metabolic function in obesity. Diabetes 2005, 54:1082-1089.
43. Rivera L, Moron R, Sanchez M, Zarzuelo A, Galisteo M: Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. Obesity (Silver Spring) 2008, 16:2081-2087.
44. Chauhan SD, Seggara G, Vo PA, Macallister RJ, Hobbs AJ, Ahluwalia A: Protection against lipopolysaccharide-induced endothelial dysfunction in resistance and conduit vasculature of iNOS knockout mice. FASEB J 2003, 17:773-775.
45. Cuzzocrea S, Mazzon E, Di Paola R, Esposito E, Macarthur H, Matuschak GM, Salvemini D: A role for nitric oxide-mediated peroxynitrite formation in a model of endotoxin-induced shock. J Pharmacol Exp Ther 2006, 319:73-81.